结直肠癌患者血清可溶性CD26增高及其意义

Increased Serum Soluble CD26 in Colorectal Cancer Patients and Its Clinical Significance

目的评价血清可溶性CD2(6sCD26)对结直肠癌的诊断价值。方法收集我院59例结直肠癌患者、51例结直肠良性疾病患者和41例健康对照患者的血清,采用ELISA法检测血清中sCD26浓度。采用受试者工作曲线(ROC)法评价血清sCD26对结直肠癌的诊断价值,并采用logistic回归分析其对结直肠癌的关系是否独立于癌胚抗原(CEA)。结果结直肠癌患者血清sCD26水平较健康对照组和结直肠良性疾病组患者增高(P<0.01),但sCD26在Dukes不同分期间的差异无统计学意义(P=0.78)。sCD26诊断结直肠癌的曲线下面积为0.72〔95%可信区间(CI)为0.63～0.82,P<0.01〕,最佳诊断界值为526μg/L。sCD26的诊断敏感度和特异度分别为0.59(95%CI为0.48～0.72)和0.80(95%CI为0.67～0.90)。在包含了CEA的logistic回归模型中,sCD26阳性(≥526μg/L)的优势比为5.17(95%CI为1.72～15.53,P<0.01)。DukesA期结直肠癌患者sCD26较CEA具有更高的阳性率(P=0.03),但Dukes B、C和D期结直肠癌患者sCD26的阳性率均低于CEA(P<0.05)。结论sCD26对结直肠癌具有较高且独立于CEA的诊断价值。与CEA相比,sCD26更具有成为结直肠癌早期标志物的潜质。

Objective To evaluate the diagnostic efficiency of serum soluble CD26 （sCD26） on the diagnosis of colorectal cancer. Methods The serum sCD26 concentration of 59 colorectal cancer patients, 51 colorectal benign disease patients, and 41 healthy volunteers were detected by ELISA. The diagnostic efficiency of sCD26 and carcinoma embryonic antigen （CEA） was assessed by receiver operating characteristics （ROC） analysis. The association between sCD26 and colorectal cancer was assessed by logistic regression which included CEA in the model. Results Increased serum sCD26 was observed in colorectal cancer patients （P 〈 0. 01）, but the differences of sCD26 in different Dukes stages were not statistic significance （P： 0. 78）. The area under cure （AUC） of sCD26 confirmed by ROC analysis was 0. 72 95% confidence interval （CI） ： 0. 63-0. 82, P 〈 0. 011. The diagnostic sensitivity and specificity for sCD26 at 526 tg/L, the optimal diagnostic threshold, were 0.59 （95% CI： 0. 48-0.72） and 0.80 （95% CI： 0. 67-0. 90） , respectively. Positive serum sCD26 was associated with colorectal cancer after adjusted for CEA with odds ration （OR） 5.17 （95% CI： 1.72-15.53, P〈0. 01）, as confirmed by logistic regression. Increased positive rate of serum sCD26 was observed in patients at Dukes A stage （P=0. 03）, but not Dukes B, C, and D stage （P〈0. 05）. Conclusions Serum sCD26 has high diagnostic performance for colorectal cancer. The association of sCD26 is independent of serum CEA. Compared to serum CEA, sCD26 has more potential to be an early biomarker for colorectal cancer diagnosis.